The Effects of Celecoxib or Naproxen on Blood Pressure in Pediatric Patients with Juvenile Idiopathic Arthritis
Autor: | Bonita Falkner, P. Bhadra Brown, L. Zemel, Dinu Iorga, Manuela F. Berger, Robert W. Nickeson |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2015 |
Předmět: |
musculoskeletal diseases
medicine.medical_specialty Naproxen NSAIDs Diastole Arthritis Gastroenterology Internal medicine medicine Juvenile Adverse effect skin and connective tissue diseases Original Research celecoxib business.industry General Engineering lcsh:RJ1-570 blood pressure lcsh:Pediatrics medicine.disease Confidence interval Blood pressure Celecoxib juvenile idiopathic arthritis business medicine.drug Biomedical engineering |
Zdroj: | Clinical Medicine Insights: Pediatrics, Vol 9 (2015) Clinical Medicine Insights. Pediatrics Clinical Medicine Insights: Pediatrics, Vol 2015, Iss 9, Pp 55-62 (2015) |
ISSN: | 1179-5565 |
Popis: | Background Selective and nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) are indicated for the treatment of juvenile idiopathic arthritis (JIA). However, the effect of NSAIDs on blood pressure (BP) in children has not been rigorously examined. Methods In this randomized, double-blind, multicenter, active-controlled, 6-week trial, the safety and efficacy of celecoxib (50 mg twice daily [bid] or 100 mg bid) or naproxen (7.5 mg/kg bid) was evaluated in patients aged 2–17 years with JIA. Results The least squares (LS) mean difference (celecoxib – naproxen) in change from baseline to week 6/final visit in systolic BP was 1.10 (90% confidence interval, -0.56, 2.76). No significant LS mean differences in diastolic BP relative to baseline were reported. Treatment-emergent adverse events occurred in 48% of patients in each treatment group. Conclusion Both celecoxib and naproxen had no impact on BP, and both treatments had comparable safety profiles. Celecoxib, or naproxen, could be seen as suitable treatment options for pediatric patients with JIA. |
Databáze: | OpenAIRE |
Externí odkaz: |